Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Ascentage Pharma Group Corp. Ltd.
DescriptionSecond generation BCL-2/Bcl-XL inhibitor
Molecular Target B cell lymphoma 2 (BCL-2) (BCL2) ; Bcl-XL
Mechanism of ActionBcl-2 inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today